Compare Bristol-Myers Squibb Co (BMY) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hyatt Hotels Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while Hyatt Hotels Corporation trades at $177.39 (market cap $16.27B). The key difference: Bristol-Myers Squibb Co is far larger — about 8× Hyatt Hotels Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | H | |
|---|---|---|
Market Cap | $129.94B | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $202.09 |
52-Week Low | $42.60 | $135.42 |
Enterprise Value | $163.92B | $20.17B |
Dividend Yield | 3.96% | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Hyatt Hotels Corp (H) trades at $176.29, up 3.65% today, with a bearish technical outlook but strong recent earnings beats. The stock shows a high P/E of 213.14 and modest net margin of 1.1%, while cash flow trends are volatile. Analyst consensus is mixed with a $199.55 price target, and recent news highlights valuation concerns amid growth initiatives.
Outlook balances operational momentum from fee growth and RevPAR gains against rich valuation and debt risks. Investment opportunity lies in sustained travel demand, but risks include project delays, regional weakness, and high leverage. The stock requires patience for growth to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
